34.1948  0.166 (0.49%)		04-13 16:00
Open: 34.16 High: 34.2 Volume: 1,017		Pre. Close: 34.0292 Low: 33.81 Market Cap: 29(M)

Short term
Mid term
Targets	6-month :	40.78	1-year :	47.63
Resists	First :	34.91	Second :	40.78
Pivot price	33.9
Supports	First :	33.63	Second :	32.84
MAs	MA(5) :	34.25	MA(20) :	33.8
	MA(100) :	33.67	MA(250) :	29.58
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	76.7	D(3) :	80.7
RSI	RSI(14): 51.2
52-week	High :	35.61	Low :	23.53

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ FTXH ] has closed below upper band by 36.5%. Bollinger Bands are 11.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	34.25 - 34.44	34.44 - 34.62
Low:	33.3 - 33.55	33.55 - 33.78
Close:	33.83 - 34.19	34.19 - 34.53

The First Trust Nasdaq Pharmaceuticals ETF is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield, before the Fund's fees and expenses, of an index called the Nasdaq US Smart Pharmaceuticals Index. The Fund seeks to replicate the holdings and weightings of the Nasdaq US Smart Pharmaceuticals Index so as to generate performance results 95% correlated to that of the Nasdaq US Smart Pharmaceuticals Index.

Sat, 11 Apr 2026
First Trust NASDAQ Pharmaceuticals ETF declares quarterly distribution of $0.0573 - MSN

Sat, 15 Nov 2025
Eli Lilly Supremacy: The Single Stock Steering Pharma ETF Performance - First Trust Nasdaq Pharmaceutical - Benzinga

Thu, 16 Oct 2025
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook - TradingView — Track All Markets

Thu, 17 Jul 2025
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook - Yahoo Finance

Mon, 12 May 2025
Pharma ETFs in Focus on Trump's Drug Price Overhaul - Yahoo Finance

Wed, 17 Apr 2024
The 5 Best Pharmaceutical ETFs of 2023 - ETF.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.